Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease

ClinicalTrials.gov ID: NCT02494778

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02494778. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 2:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).

Study identification

NCT ID
NCT02494778
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Prilenia
Industry
Enrollment
248 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
21 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 24, 2015 (Actual)
Primary completion
Jan 12, 2018 (Actual)
Completion
Jan 12, 2018 (Actual)
Last update posted
Sep 17, 2021

2015 – 2018

United States locations

U.S. sites
11
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
Teva Investigational Site 12204 Los Angeles California 90095 —
Teva Investigational Site 12201 Englewood Colorado 80113 —
Teva Investigational Site 12196 Washington D.C. District of Columbia 20007 —
Teva Investigational Site 12206 Baltimore Maryland 21287 —
Teva Investigational Site 12200 Manhasset New York 11030 —
Teva Investigational Site 12203 New York New York 10032 —
Teva Investigational Site 12198 Rochester New York 14618 —
Teva Investigational Site 12211 Winston-Salem North Carolina 27157 —
Teva Investigational Site 12209 Pittsburgh Pennsylvania 15213 —
Teva Investigational Site 12208 Salt Lake City Utah 84108 —
Teva Investigational Site 12210 Richmond Virginia 23230 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02494778, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 17, 2021 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.